Where to find us at the ISSX Europe 2026!

Visit us at ISSX Europe – Stand # 19

Join us at our booth to discover how you can capture critical biological mechanisms that conventional models often miss. With our multi-organ microphysiological systems (MPS), you can isolate tissue-specific ADME parameters to de-risk your pipeline with human-relevant translational data.

Our approach enables physiological profiling across critical pharmacokinetic areas. This includes evaluating human oral bioavailability through first-pass metabolic and individual gut and liver contributions, as well as generating precise metabolism, clearance, and metabolite production data. Furthermore, our platform allows you to quantify dynamic transport for absorption profiles and separate intricate drug-drug interaction (DDI) risks across organs.

So, let’s change the game, together with a platform like no other. Meet the new easy to adopt, adapt and scale MPS – PhysioMimix® Core. Interact with its Multi-chip consumables plates and explore our range of validated protocols.

Our dedicated team will be at hand to answer your questions and share over a decade of Organ‑on‑a‑Chip (OOC)/ MPS expertise. Discover how you can enhance data translatability, optimize in vivo study design, and support confident preclinical decision‑making using more predictive, human‑relevant approaches that are in line with regulatory roadmaps to reduce animal testing.

Book a meeting at ISSX Europe 2026

A primary human Gut/Liver microphysiological system to estimate human oral bioavailability.

Predicting human oral bioavailability remains a major challenge in drug development due to the complex interplay of biological and physicochemical processes across the gut and liver. Traditional preclinical tools such as the Caco‑2 assay and isolated hepatocytes provide only isolated snapshots of this process and often fail to reproduce integrated human physiology. Animal studies can offer whole‑organism context but frequently diverge from human outcomes, while PBPK models rely heavily on high‑quality, human‑relevant input data to perform reliably.

Here, we introduce a primary human Gut/Liver Microphysiological System (MPS) that combines intestinal absorption, gut wall metabolism, hepatic clearance, and transporter activity within a single, physiologically relevant platform. The system combines a primary human jejunum tissue model with primary human hepatocyte microtissues in a dual‑organ, flow‑linked configuration, enabling mechanistic assessment of drug disposition across the first‑pass barrier.

Using case studies including midazolam, dextromethorphan, and ritonavir‑boosted darunavir, we demonstrate how continuous sampling and in silico modelling translate MPS data into quantitative estimates of Fa, Fg, and Fh. The model captures donor‑specific variability in CYP2D6 activity and resolves gut versus liver contributions to clearance. The platform also reproduces key features of drug-drug interactions, including CYP3A4 inhibition and altered absorption through the gut barrier.

Together, these findings show that the Gut/Liver MPS provides a mechanistic, human‑relevant approach for estimating oral bioavailability from a single integrated experiment, strengthening PBPK model inputs and supporting more confident decision‑making in early drug development.

Date: 01 July 2026, Wednesday

Time: 17:00 – 18:30

Session: Plenary Session 2

Room: TBC

Presenters: Dr. Yassen Abbas